Request Number | Guideline Page | Specific change request | Panel Decision | Comment | Institution Vote |
---|---|---|---|---|---|
4790 - Internal Request | WM/LPL-B (2 of 4) and WM/LPL-B (3 of 4) | Consider adding a footnote to rituximab regimens: Obinutuzumab may be considered in patients who are unable to tolerate rituximab (Wróbel T, et al. Hemasphere 2023;7:e4339598. doi: 10.1097/01.HS9.0000971308.43395.98). | Change made | The panel agreed to add the footnote for rituximab regimens. |
Yes: 18 No: 2 Abstain:1 Absent:13 |